Copyright © Inderes 2011 - present. All rights reserved.
Log in to receive notifications.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Magle Chemoswed Holding

29.4

 

SEK

 

0 %

Less than 1K followers

MAGLE

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus
Compare
0%
-5.77%
-15.52%
-15.52%
-23.93%
-8.34%
+4.66%
-
+46.32%

The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed, a contract development and manufacturing organization (CDMO). Magle PharmaCept, an established sales and marketing company for the development and direct sales of the Groups medical technology products, and Magle Biopolymers A/S, a specialized manufacturing organization of Dextran technology.

Read more
Market cap
603.17M SEK
Turnover
95.78K SEK
Revenue
236.04M
EBIT %
9.84 %
P/E
0.67
Dividend yield-%
-
Financial calendar
26/5
2025

General meeting '25

All
Press releases
3rd party
ShowingAll content types
Press release3/28/2025, 1:35 PM

Magle Chemoswed Holding AB (publ): Magle Group till BioStock: We live by the mantra `earn it before you burn it'

Magle Chemoswed Holding
Press release3/28/2025, 1:35 PM

Magle Chemoswed Holding AB (publ): Magle Group to BioStock: We live by the mantra `earn it before you burn it'

Magle Chemoswed Holding
Press release3/27/2025, 12:28 PM

Redeye: Magle Chemoswed Q4 - Delivering on its growth trajectory

Magle Chemoswed Holding

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release3/27/2025, 7:30 AM

Magle Chemoswed Holding Reports Financial Results For Fourth Quarter 2024

Magle Chemoswed Holding
Press release3/24/2025, 11:35 AM

Magle Chemoswed Holding AB (publ): BioStock: Magle Group launches multicenter trial with pancreatic leakage indicator

Magle Chemoswed Holding
Press release3/19/2025, 7:15 AM

Magle Group initiates Randomized Controlled Multicenter Trial with leading European university hospitals to explore SmartPAN® efficacy

Magle Chemoswed Holding
Regulatory press release2/26/2025, 5:00 PM

Ingela Fritzson resigns from the Board of Directors of Magle Group

Magle Chemoswed Holding
Press release2/17/2025, 8:00 AM

Magle Group is pleased to announce Magle PharmaCept’s participation in the DPC, German Pancreatic Club congress, set to take place February 27-March 1, 2025, in Heidelberg, Germany.

Magle Chemoswed Holding
Regulatory press release2/14/2025, 7:05 AM

Magle Group Announces Revised Publication Date for Q4 2024 and Full-Year 2024 Reports Due to Ongoing Consolidation Process

Magle Chemoswed Holding
Regulatory press release1/9/2025, 8:45 PM

Magle Group offentliggör tilldelning i den riktade emissionen

Magle Chemoswed Holding
Regulatory press release1/9/2025, 8:45 PM

Magle Group announces allocation in the directed share issue

Magle Chemoswed Holding
Regulatory press release12/30/2024, 11:30 AM

Kommuniké från extra bolagsstämma i Magle Chemoswed Holding AB

Magle Chemoswed Holding
Regulatory press release12/30/2024, 11:30 AM

Bulletin from the extraordinary general meeting in Magle Chemoswed Holding AB

Magle Chemoswed Holding
Regulatory press release12/20/2024, 2:30 PM

Magle Group tillförs cirka 36,8 MSEK i företrädesemissionen

Magle Chemoswed Holding
Regulatory press release12/20/2024, 2:30 PM

Magle Group raises approximately SEK 36.8 million in the rights issue

Magle Chemoswed Holding
Regulatory press release12/16/2024, 2:30 PM

Magle Group publishes supplementary prospectus

Magle Chemoswed Holding
Regulatory press release12/16/2024, 2:30 PM

Magle Group offentliggör tilläggsprospekt

Magle Chemoswed Holding
Press release12/16/2024, 9:40 AM

Magle Group Approves Multi-Centre Clinical Trial in Genicular Artery Embolisation for Osteoarthritis Pain Relief

Magle Chemoswed Holding
Regulatory press release12/12/2024, 9:45 PM

Kallelse till extra bolagsstämma i Magle Chemoswed Holding AB (publ)

Magle Chemoswed Holding
Regulatory press release12/12/2024, 9:45 PM

Notice to the extraordinary general meeting in Magle Chemoswed Holding AB (publ)

Magle Chemoswed Holding
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Privacy preferences

Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.